-- Days : -- HRS : -- MIN : -- SEC

Register Now →

Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|August 14, 2024

Understanding the Differential Diagnosis and Distinctions Between Overt and Covert Hepatic Encephalopathy

The panel explains that diagnosing hepatic encephalopathy (HE) involves excluding other potential causes of mental status changes, with HE ranging from subtle to severe impairment.

Episodes in this series

EP. 1 Epidemiology and Trends in Hepatic Encephalopathy (HE) in the United States

EP. 1 Epidemiology and Trends in Hepatic Encephalopathy (HE) in the United States

EP. 2 Clinical Features and Risk Factors of Hepatic Encephalopathy and Their Impact on Patient Care

EP. 2 Clinical Features and Risk Factors of Hepatic Encephalopathy and Their Impact on Patient Care

EP. 3 Understanding the Differential Diagnosis and Distinctions Between Overt and Covert Hepatic Encephalopathy

EP. 3 Understanding the Differential Diagnosis and Distinctions Between Overt and Covert Hepatic Encephalopathy

EP. 4 Navigating the Clinical and Economic Landscape of Hepatic Encephalopathy (HE)

EP. 4 Navigating the Clinical and Economic Landscape of Hepatic Encephalopathy (HE)

EP. 5 Optimal Strategies for Managing the Burdens Associated with Hepatic Encephalopathy (HE)

EP. 5 Optimal Strategies for Managing the Burdens Associated with Hepatic Encephalopathy (HE)

EP. 6 Optimizing Therapy Goals and Managing Overt Hepatic Encephalopathy (HE)

EP. 6 Optimizing Therapy Goals and Managing Overt Hepatic Encephalopathy (HE)

EP. 7 Guidelines in Action and Navigating Overt Hepatic Encephalopathy (HE) Management

EP. 7 Guidelines in Action and Navigating Overt Hepatic Encephalopathy (HE) Management

EP. 8 Strategies for Addressing Precipitating Factors and Comorbidities in Hepatic Encephalopathy (HE)

EP. 8 Strategies for Addressing Precipitating Factors and Comorbidities in Hepatic Encephalopathy (HE)

EP. 9 Optimizing Continuity of Care to Enhance Patient Outcomes and Reduce Hospitalizations in Hepatic Encephalopathy (HE)

EP. 9 Optimizing Continuity of Care to Enhance Patient Outcomes and Reduce Hospitalizations in Hepatic Encephalopathy (HE)

EP. 10 Coordinated Care Strategies and Enhancing Patient Outcomes in Hepatic Encephalopathy (HE)

EP. 10 Coordinated Care Strategies and Enhancing Patient Outcomes in Hepatic Encephalopathy (HE)

EP. 11 Navigating Insurance Challenges and Transitions of Care in Hepatic Encephalopathy (HE)

EP. 11 Navigating Insurance Challenges and Transitions of Care in Hepatic Encephalopathy (HE)

EP. 12 Diagnosis of hepatic encephalopathy (HE) with a Case Study

EP. 12 Diagnosis of hepatic encephalopathy (HE) with a Case Study

EP. 13 Collaborating with Payers to Improve Outcomes in HE

EP. 13 Collaborating with Payers to Improve Outcomes in HE

EP. 14 Final Thoughts on Advancing Hepatic Encephalopathy (HE) Management

EP. 14 Final Thoughts on Advancing Hepatic Encephalopathy (HE) Management

This series was supported by Salix Pharmaceuticals.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Trending on AJMC

Adam Kittai, MD, on Sequencing, Cost, and the Road to CLL Cure

COVID-19 May Follow a Different Seasonal Pattern Than Influenza, RSV

Real-World Data Show MASH Progresses Faster Than Trials Suggest

Sarcoma's Rarity Limits Trials and Biomarker-Driven Treatment Options: Alexander Spira, MD, PhD, FACP, FASCO

SYNC-T: Immunotherapy Platform Brings 4-Part Attack in Prostate Cancer, With More Trials Planned